Additional data to be presented from the ongoing phase 1/2 study of BION-1301 in patients with IgA nephropathy, including biomarker and proteinuria reductions
Several presentations on the atrasentan clinical program, including translational research demonstrating ETA activation is associated with clinical progression in IgA nephropathy
Chinook to host investor conference call and webcast on November 4, 2021 to review abstracts and provide updates on the company’s pipeline
Investor Conference Call Details
To access the call, please dial (844) 309-0604 (domestic) or (574) 990-9932 (international) and provide the Conference ID 1381696 to the operator.
To access the live webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Chinook’s website. The archived webcast will remain available for replay on Chinook’s website for 90 days.
https://finance.yahoo.com/news/chinook-therapeutics-announces-upcoming-data-200500385.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.